目的

对南通市肿瘤医院2002 年1 月至2014 年12 月以医院为基础的启东、海门籍乳腺癌登记病例作生存率分析,为乳腺癌防治提供依据。

方法

采用主动随访与被动随访相结合的方法,对癌症登记数据库中来自南通地区的335 例启东、海门籍乳腺癌住院患者开展生存结局的随访,随访截止于2016 年3 月31 日。 采用寿命表法计算观察生存率,用Wilcoxon 检验进行生存率的比较分析。

结果

在南通市肿瘤医院住院的335 例启东籍和海门籍乳腺癌患者中,随访获得癌症生存结局信息者308 例,随访率为91.9%(308/335);失访27 例,失访率为8.1%(27/335)。 308 例患者中有4 例为男性,故仅将304 例女性纳入本研究。 患者首次入院时中位年龄为54.0 岁(年龄范围18.0 ～81.9 岁),其中,40.0 ～59.9 岁者共计197 例,占64.8%(197/304)。 女性患者1、3、5、10 年的观察生存率分别为86.8%、69.5%、61.0%及46.6%。 启东籍与海门籍乳腺癌患者5 年观察生存率分别为65.7% 和56.9%,差异无统计学意义(Z=1.423,P＞0.050),并且,2 组患者间累积生存率差异也无统计学意义(Gehan 值为1.695,P=0.193)。

结论

本研究中启东、海门籍女性乳腺癌住院患者的生存率相当,该结果可为乳腺癌综合治疗效果的评估提供参考依据。

Objective

To analyze the survival rate of breast cancer inpatients with Qidong and Haimen household registration in Nantong Tumor Hospital from January 2002 to December 2014 and provide references for prevention and treatment of breast cancer.

Methods

With active and passive follow-up methods, the survivals of 335 inpatients with Qidong and Haimen household registration in Nantong Area recorded in cancer databank were investigated until March 31,2016. Survival probability was estimated using the life-table method and Wilcoxon test was used for survival comparison.

Results

In all 335 patients, the outcomes of 308 patients were identified, with a follow-up rate of 91.9% and a missing rate of 8.1% (27 cases). There were 4 males and 304 females, so only female patients were included in this analysis. The median age of the first hospitalization was 54.0 (18.0-81.9) years old. The most commonly affected age was 40-59 years,accounting for 64.8%. The 1-, 3-, 5-, and 10-year observed survival of female breast cancer patients was 86.8%,69.5%,61.0% and 46.6%, respectively. The 5-year observed survival was 65.7% in patients with Qidong household registration and 56.9% in Haimen household registration, indicating no significant difference(Z=1.423,P ＞0.050). Their cumulative survival rates presented no significant difference (Gehan value 1.695,P=0.193).

Conclusion

The breast cancer inpatients with Qidong and Haimen household registration have similar survival, which can provide references for the evaluation of comprehensive treatment outcome in female breast cancer patients.